Suchergebnisse - "Sugawara, Shunichi"

PubPharm (209)

1

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2024

von Wu, Y. | Dziadziuszko, R. | Ahn, J. | +120

2

Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC-A Brief Report From the CROWN Study

enthalten in: JTO clinical and research reports | 2024

von Teraoka, S. | Hayashi, H. | Goto, Y. | +8

3

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer : A Phase 3 Randomized Clinical Trial

enthalten in: JAMA oncology | 2024

von Shiraishi, Y. | Kishimoto, J. | Sugawara, S. | +25

4

Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816

enthalten in: Cancer science | 2024

von Mitsudomi, T. | Ito, H. | Okada, M. | +16

5

Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases

enthalten in: Cancer reports (Hoboken, N.J.) | 2024

von Murakami, Y. | Kawashima, Y. | Chiba, S. | +13

6

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab : Results from the Small Cell Lung Cancer Cohort

enthalten in: Cancer research communications | 2024

von Nishio, M. | Murakami, S. | Kawakami, H. | +17

7

A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer : TORG2241 (UBE-Q)

enthalten in: Clinical lung cancer | 2024

von Nakamichi, S. | Kubota, K. | Matsuyama, K. | +20

8

Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase ( ALK)‐positive lung cancer and multiple brain metastases

enthalten in: Cancer Reports | 2024

von Murakami, Y. | Kawashima, Y. | Chiba, S. | +13

9

Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007) : A Randomized, Double-Blind, Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Yang, J. | Han, B. | De La Mora Jiménez, E. | +16

10

Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Liu, S. | Mok, T. | Nabet, B. | +18

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[21]